Carcinogenesis, Vol. 23, No. 3, 499-510,
March 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis
1 Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA,
2 AMC Cancer Research Center, Denver, CO 80214, USA and
3 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
This study reports in vivo therapeutic efficacy of silymarin against skin tumors with mechanistic rationale. 7,12-Dimethylbenz[a]anthracene–12-O-tetradecanoyl-phorbol-13-acetate (DMBA–TPA)-induced established skin papilloma (tumor)-bearing SENCAR mice were fed with 0.5% silymarin in AIN-93M-purified diet (w/w), and both tumor growth and regression were monitored during 5 weeks of feeding regimen. Silymarin feeding significantly inhibited (74%, P < 0.01) tumor growth and also caused regression (43%, P < 0.01) of established tumors. Proliferating cell nuclear antigen and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling immunohistochemical staining of tumors showed that silymarin decreases proliferation index by 48% (P < 0.001) and increases apoptotic index by 2.5-fold (P < 0.001), respectively. Skin tumor growth inhibition and regression by silymarin were also accompanied by a strong decrease (P < 0.001) in phospho-ERK1/2 levels in tumors from silymarin-fed mice compared with controls. In the studies evaluating bioavailability and physiologically achievable level of silymarin (as silibinin) in plasma, skin tumor, skin, liver, lung, mammary gland and spleen, we found 10, 6.5, 3.1, 13.7, 7.7, 5.9 and 4.4 µg silibinin/ml plasma or per gram tissue, respectively. In an attempt to translate these findings to human skin cancer and to establish biological significance of physiologically achievable level, effect of plasma concentration of silibinin was next examined in human epidermoid carcinoma A431 cells. Silibinin treatment of cells in culture at 12.5, 25 (plasma level) and 50 µM doses resulted in 30–74% (P < 0.01–0.001) growth inhibition and 7–42% death of A431 cells in a dose- and time-dependent manner; apoptosis was identified as a cell death response by silibinin. Similar silibinin treatments also resulted in a significant decrease in phospho-mitogen-activated protein kinase/extracellular signal-regulated protein kinase 1/2 (MAPK/ERK1/2) levels, but an up-regulation of stress-activated protein kinase/jun NH2-terminal kinase (SAPK/JNK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) activation in A431 cells. The use of MEK1 inhibitor, PD98059, showed that inhibition of ERK1/2 signaling, in part, contributes to silibinin-caused cell growth inhibition. Together, the data suggest that an inhibition of ERK1/2 activation and an increased activation of JNK1/2 and p38 by silibinin could be possible underlying molecular events involved in inhibition of proliferation and induction of apoptosis in A431 cells. These data suggest that silymarin and/or its major active constituent silibinin could be an effective agent for both prevention and intervention of human skin cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. T. Bility, M. K. Devlin-Durante, N. Blazanin, A. B. Glick, J. M. Ward, B. H. Kang, M. J. Kennett, F. J. Gonzalez, and J. M. Peters Ligand activation of peroxisome proliferator-activated receptor {beta}/{delta} (PPAR{beta}/{delta}) inhibits chemically induced skin tumorigenesis Carcinogenesis, December 1, 2008; 29(12): 2406 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Velmurugan, R. P. Singh, A. Tyagi, and R. Agarwal Inhibition of Azoxymethane-Induced Colonic Aberrant Crypt Foci Formation by Silibinin in Male Fisher 344 Rats Cancer Prevention Research, October 1, 2008; 1(5): 376 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Comelli, U. Mengs, C. Schneider, and M. Prosdocimi Toward the Definition of the Mechanism of Action of Silymarin: Activities Related to Cellular Protection From Toxic Damage Induced by Chemotherapy Integr Cancer Ther, June 1, 2007; 6(2): 120 - 129. [Abstract] [PDF]
|
|
|
|
|
|
G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 R. P. Singh, S. Dhanalakshmi, S. Mohan, C. Agarwal, and R. Agarwal Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-{kappa}B in mouse epidermal JB6 cells Mol. Cancer Ther., May 1, 2006; 5(5): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Ruiz, M. Santos, M. F. Lara, C. Segrelles, C. Ballestin, and J. M. Paramio Unexpected Roles for pRb in Mouse Skin Carcinogenesis Cancer Res., November 1, 2005; 65(21): 9678 - 9686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kohno, R. Suzuki, S. Sugie, H. Tsuda, and T. Tanaka Dietary Supplementation with Silymarin Inhibits 3,2'-Dimethyl-4-Aminobiphenyl-Induced Prostate Carcinogenesis in Male F344 Rats Clin. Cancer Res., July 1, 2005; 11(13): 4962 - 4967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dhanalakshmi, C. Agarwal, R. P. Singh, and R. Agarwal Silibinin Up-regulates DNA-Protein Kinase-dependent p53 Activation to Enhance UVB-induced Apoptosis in Mouse Epithelial JB6 Cells J. Biol. Chem., May 27, 2005; 280(21): 20375 - 20383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Davis-Searles, Y. Nakanishi, N.-C. Kim, T. N. Graf, N. H. Oberlies, M. C. Wani, M. E. Wall, R. Agarwal, and D. J. Kroll Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells Cancer Res., May 15, 2005; 65(10): 4448 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gu, S. Dhanalakshmi, R. P. Singh, and R. Agarwal Dietary Feeding of Silibinin Prevents Early Biomarkers of UVB Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1344 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Padmavathi, P. C. Rath, A. R. Rao, and R. P. Singh Roots of Withania somnifera Inhibit Forestomach and Skin Carcinogenesis in Mice Evid. Based Complement. Altern. Med., March 1, 2005; 2(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhanalakshmi, G.U. Mallikarjuna, R. P. Singh, and R. Agarwal Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis Carcinogenesis, August 1, 2004; 25(8): 1459 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, G. Sharma, G. U. Mallikarjuna, S. Dhanalakshmi, C. Agarwal, and R. Agarwal In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate: Induction of Insulin-Like Growth Factor Binding Protein-3 and Inhibition of Vascular Endothelial Growth Factor Clin. Cancer Res., January 1, 2004; 10(1): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Tyagi, R. P. Singh, C. Agarwal, D. C. F. Chan, and R. Agarwal Silibinin Strongly Synergizes Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth Inhibition, G2-M Arrest, and Apoptosis Clin. Cancer Res., November 1, 2002; 8(11): 3512 - 3519. [Abstract] [Full Text] [PDF]
|
|